OBJECTIVES To evaluate whether oral folic acid supplementation might improv
e endothelial function in the arteries of asymptomatic adults with hyperhom
ocystinemia.
BACKGROUND Hyperhomocystinemia is an independent risk factor for endothelia
l dysfunction and occlusive vascular disease. Folic acid supplementation ca
n lower homocystine levels in subjects with hyperhomocystinemia; however, t
he effect of this on arterial physiology is not known.
METHODS Adults subjects were recruited from a community-based atheroscleros
is study on healthy volunteers aged 40 to 70 years who had no history of hy
pertension, diabetes mellitus, hyperlipidemia, ischemic heart disease or fa
mily history of premature atherosclerosis (n = 89). Seventeen subjects (age
d 54 +/- 10 years, 15 male) with fasting total homocystine levels above 75t
h percentile (mean, 9.8 +/- 2.8 mu mol/liter) consented to participate in a
double-blind, randomized, placebo-controlled and crossover trial; each sub
ject received oral folic acid (10 mg/day) and placebo for 8 weeks, each sep
arated by a washout period of four weeks. Flow-mediated endothelium-depende
nt dilation (percent increase in diameter) of the brachial artery was asses
sed by high resolution ultrasound, before and after folic acid or placebo s
upplementation.
RESULTS Compared with placebo, folic acid supplementation resulted in highe
r serum folate levels (66.2 +/- 7.0 vs. 29.7 +/- 14.8 nmol/liter; p < 0.001
), lower total plasma homocystine levels (8.1 +/- 3.1 vs. 9.5 +/- 2.5 mu mo
l/liter, p = 0.03) and significant improvement in endothelium dependent dil
ation (8.2 +/- 1.6% vs. 6 +/- 1.3%, p < 0.001). Endothelium-independent res
ponses to nitroglycerin were unchanged. No adverse events were observed.
CONCLUSIONS Folic acid supplementation improves arterial endothelial functi
on in adults with relative hyperhomocystinemia, with potentially beneficial
effects on the atherosclerotic process. (C) 1999 by the American College o
f Cardiology.